CB 109
Alternative Names: CB-109Latest Information Update: 20 Apr 2022
Price :
$50 *
At a glance
- Originator Chimeron Bio
- Class COVID-19 vaccines; Protein vaccines; RNA vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical COVID 2019 infections
Most Recent Events
- 29 Mar 2022 Preclinical trials in COVID-2019 infections (Prevention) in USA (Parenteral) prior to March 2022 (Chimeron Bio pipeline, March 2022)